Alain De Pover

Alain De Pover

UNVERIFIED PROFILE

Are you Alain De Pover?   Register this Author

Register author
Alain De Pover

Alain De Pover

Publications by authors named "Alain De Pover"

Are you Alain De Pover?   Register this Author

12Publications

515Reads

42Profile Views

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.

Mol Cancer Ther 2014 May 7;13(5):1117-29. Epub 2014 Mar 7.

Authors' Affiliations: Novartis Institutes for BioMedical Research, Disease Area Oncology; Novartis Institutes for BioMedical Research, Global Discovery Chemistry; Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry; Novartis Pharma AG, Oncology Translational Medicine, Basel, Switzerland; Novartis Pharma AG, Oncology Translational Medicine; Novartis Institutes for BioMedical Research, Developmental and Molecular Pathways, Cambridge, Massachusetts; and Novartis Institutes for BioMedical Research, Developmental and Molecular Pathways, Shangai, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0865DOI Listing
May 2014

Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.

Bioorg Med Chem Lett 2014 May 22;24(9):2110-4. Epub 2014 Mar 22.

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2014.03.039DOI Listing
May 2014

Factors influencing the inhibition of protein kinases.

J Enzyme Inhib Med Chem 2012 Apr 3;27(2):194-200. Epub 2011 Jun 3.

Druggability-Enzymology-Profiling Unit, Oncology Research, Novartis Institutes of BioMedical Research, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/14756366.2011.583922DOI Listing
April 2012

Leveraging the contribution of thermodynamics in drug discovery with the help of fluorescence-based thermal shift assays.

J Biomol Screen 2011 Jun 25;16(5):552-6. Epub 2011 Mar 25.

Druggability-Enzymology-Profiling Unit, Oncology Research, Novartis Institutes of BioMedical Research, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1087057111399573DOI Listing
June 2011